Drugs / Obefazimod
Obefazimod
Trials 21 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07453784 | Mar → Sep 2026 expected | — | Abivax S.A. | Recruiting | No outcome recorded |
| Phase 1 | NCT05032560 | Sep 2021 → Feb 2022 | — | Abivax S.A. | Completed | No outcome recorded |
| Phase 1 | NCT05121714 | Dec 2020 → May 2021 | — | Abivax S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02731885 | Sep 2014 → Jun 2015 | — | Abivax S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02792686 | Mar → Jul 2014 | — | Abivax S.A. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02990325 | Mar 2017 → Dec 2018 | HIV infectious disease | Abivax S.A. | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT06456593 | Oct 2024 → Dec 2026 expected | Crohn jejunoileitis | Abivax S.A. | Recruiting | No outcome recorded |
| Phase 2 | NCT05177835 | Dec 2021 → Mar 2028 expected | ulcerative colitis | Abivax S.A. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04023396 | Jan 2020 → Feb 2023 | ulcerative colitis | Abivax S.A. | Completed | No outcome recorded |
| Phase 2 | NCT04049448 | Oct 2019 → Jan 2023 | rheumatoid arthritis | Abivax S.A. | Completed | No outcome recorded |
| Phase 2 | NCT03760003 | Aug 2019 → Apr 2021 | ulcerative colitis | Abivax S.A. | Completed | No outcome recorded |
| Phase 2 | NCT03813199 | Jul 2019 → Apr 2021 | rheumatoid arthritis | Abivax S.A. | Completed | No outcome recorded |
| Phase 2 | NCT03368118 | Jan 2018 → Jul 2022 | ulcerative colitis | Abivax S.A. | Completed | No outcome recorded |
| Phase 2 | NCT03093259 | Nov 2017 → Jul 2018 | ulcerative colitis | Abivax S.A. | Completed | No outcome recorded |
| Phase 2 | NCT02735863 | May 2016 → Aug 2017 | HIV infectious disease | Abivax S.A. | Completed | No outcome recorded |
| Phase 2 | NCT02452242 | Jan → Dec 2015 | HIV infectious disease | Abivax S.A. | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03905109 | Sep 2022 | Crohn disease | Abivax S.A. | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT04393038 | Jul 2020 → Mar 2021 | COVID-19 | Abivax S.A. | Terminated | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05535946 | Jan 2023 → Apr 2026 overdue | ulcerative colitis | Abivax S.A. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05507216 | Dec 2022 → Jun 2025 | ulcerative colitis | Abivax S.A. | Completed | No outcome recorded |
| Phase 3 | NCT05507203 | Oct 2022 → Jun 2025 | ulcerative colitis | Abivax S.A. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | obefazimod | “a first-in-class drug candidate ABX464 (obefazimod, 50 mg and 100 mg per day)” PMID 35641124 ↗ Jul 2022 |
| Known as | ABX464 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02452242 ↗ |
| Known as | SPL-464 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297344 ↗ |
| Action | Inhibit | “ABX464 is a novel antiviral that inhibits HIV RNA biogenesis.” PMID 34436569 ↗ Jun 2022 |
| Modality | Small molecule | “ABX464 (obefazimod) is a small molecule” PMID 36075249 ↗ Sep 2022 |
| Route | Oral | “The primary objective of the study was to assess the safety and tolerability of ABX464 after repeated oral administrations in subjects infected by HIV.” PMID 28507108 ↗ Jun 2017 |